{
  "docId": "019de075-5029-738c-8512-9456f77efe7c",
  "docSlug": "25c628cfc0779f52594519f9e322dc70",
  "documentTitle": "Genelux | Investor Presentation Deck | 38 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 38,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The table outlines a strategic partnership involving funding and regional commercialization rights.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-5029-738c-8512-9456f77efe7c/22",
  "deckHref": "/decks/019de075-5029-738c-8512-9456f77efe7c",
  "deckJsonHref": "/decks/019de075-5029-738c-8512-9456f77efe7c.json",
  "deckAnchorHref": "/decks/019de075-5029-738c-8512-9456f77efe7c#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.28,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "list",
      "text": "Newsoara will fully fund the US-based Genelux Phase 2 trial in NSCLC. Newsoara has development and commercialization rights in Greater China. Interim readout for one or more systemic administration trials expected as early as mid-2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b3f310e-2851-44bc-ab36-213191541e46",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.47,
        "x": 0.47,
        "y": 0.68
      },
      "kind": "paragraph",
      "text": "Genelux will have worldwide commercial rights (excluding Greater China) to all data generated from clinical trials of Olvi-Vec in China.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4a43f775-c5fd-40c2-b9db-1b33e037422d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.47,
        "x": 0.47,
        "y": 0.25
      },
      "kind": "table",
      "text": "Systemic Program: Clinical Trials table showing Sponsor, Trial Sites, Indication, Clinical Stage, Patients (est.), and Randomization.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef02453a-e5bd-455f-b116-6d309bd84539",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Validating Industry Collaboration with Newsoara BioPharma Co., Ltd",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86f08ac2-28a3-487b-bcbf-895b97c58633",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "3fd32d35-15ba-4001-81c0-26b4febd8923",
      "evidence": "list/bullet: Newsoara will fully fund the US-based Genelux Phase 2 trial in NSCLC. Newsoara has development and commercialization rights in Greater China.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}